<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418038</url>
  </required_header>
  <id_info>
    <org_study_id>LS1781</org_study_id>
    <secondary_id>NCI-2018-00057</secondary_id>
    <secondary_id>LS1781</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03418038</nct_id>
  </id_info>
  <brief_title>Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or Clonal Cytopenia of Undetermined Significance</brief_title>
  <official_title>Phase 2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed / Refractory Lymphoma and Patients With Clonal Cytopenia of Undetermined Significance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effect of ascorbic acid and combination chemotherapy in&#xD;
      treating patients with lymphoma that has come back (recurrent) or does not respond to therapy&#xD;
      (refractory) or clonal cytopenia of undetermined significance. Ascorbic acid may make cancer&#xD;
      cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to&#xD;
      stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,&#xD;
      or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may&#xD;
      kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the overall response rate (ORR) at the end of 2 cycles for intravenous (IV)&#xD;
      ascorbic acid (AA) added to standard salvage therapy compared to standard salvage therapy&#xD;
      plus normal saline in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)&#xD;
      who have relapsed within the first 24 months of end of their therapy. (Arms A versus [vs] B)&#xD;
      II. To determine the ORR at the end of 2 cycles of AA plus standard salvage chemotherapy in&#xD;
      patients with other types of relapsed lymphomas not eligible for Arms A/B (peripheral T-cell&#xD;
      lymphoma [PTCL], double-hit high grade, and Hodgkin lymphoma [HL]). (Arm C) III. To assess&#xD;
      the hematological response rate to treatment with high dose intravenous ascorbic acid (IV AA)&#xD;
      for clonal cytopenia of undetermined significance (CCUS) patients. (Arm D)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the adverse event profile of IV AA added to salvage therapy versus salvage&#xD;
      therapy plus IV saline in patients with DLBCL using both the Common Terminology Criteria for&#xD;
      Adverse Events (CTCAE) and Patient-Reported Outcomes (PRO)-CTCAE. (Arms A and B) II. To&#xD;
      compare the progression-free survival, overall survival, clinical benefit rate (those not&#xD;
      progressing), and percentage (%) transplant eligible patients proceeding to transplant of AA&#xD;
      added to salvage therapy versus salvage therapy plus IV saline in patients with DLBCL. (Arms&#xD;
      A and B) III. To compare the ORR at the end of 4 cycles for those with minor response/stable&#xD;
      disease at the end of cycle 2 who proceed to receive the additional 2 cycles of rituximab,&#xD;
      dexamethasone, cytarabine and cisplatin (RDHAP) with either AA or normal saline (NS) as&#xD;
      previously assigned. (Arms A and B) IV. To evaluate the adverse event profile, rate of&#xD;
      febrile neutropenia, overall survival, progression-free survival, and clinical benefit rate&#xD;
      of AA added to salvage therapy in patients with relapsed lymphoma. (Arm C) V. To assess&#xD;
      safety/tolerability, transfusion dependency (TD), progression-free survival (PFS), and&#xD;
      overall survival (OS) for CCUS patients receiving high dose IV AA.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Will include baseline AA levels (at Mayo Clinic Research [MCR]) and staining of pre/post&#xD;
      treatment biopsies for markers of oxidative stress generation and deoxyribonucleic acid (DNA)&#xD;
      methylation. (Arms A, B, and C Correlative Research on blood and tumor tissue) IIa. To assess&#xD;
      TET2 activity at baseline, weeks 12, 20, and 52. (Arm D correlative research) IIb. To assess&#xD;
      the association between using AA and the hydroxymethylation and methylation status&#xD;
      (gene-specific and global changes in 5mC/5hmC level) at baseline and weeks 20 and 52. (Arm D&#xD;
      correlative research) IIc. To assess the association between using IV AA and endothelial&#xD;
      dysfunction (at baseline, weeks 20, and 52). (Arm D correlative research) IId. To assess the&#xD;
      association between using IV AA and the inflammation markers. (Arm D correlative research)&#xD;
      IIe. To assess the association between using IV AA and molecular response including clonal&#xD;
      dynamics (new mutations and variant allele frequency [VAF]) (at baseline, weeks 20, and 52).&#xD;
      (Arm D correlative research)&#xD;
&#xD;
      OUTLINE: Patients with DLBCL are randomized to Arms A or B. Patients with other lymphomas are&#xD;
      assigned to Arm C. Patients with CCUS are assigned to Arm D.&#xD;
&#xD;
      Arm A: Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and&#xD;
      rituximab intravenously (IV), ifosfamide IV, carboplatin IV and etoposide IV on days 1-3.&#xD;
      Patients who achieve minor response (MR) or stable disease (SD) after 2 cycles may receive&#xD;
      rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO.&#xD;
      Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      ARM B: Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and&#xD;
      19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days&#xD;
      1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin&#xD;
      IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days&#xD;
      for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM C: Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients&#xD;
      also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and&#xD;
      dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO,&#xD;
      or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and&#xD;
      dexamethasone IV or PO according standard regimen schedule. Treatment repeats every 21 days&#xD;
      for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen.&#xD;
&#xD;
      ARM D: Patients receive ascorbic acid IV three times a week (TIW). Treatments repeat every 28&#xD;
      days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      In Arms A, B, and C, patients who achieve complete response (CR), partial response (PR) or MR&#xD;
      may undergo stem cell transplantation.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months, then every 6&#xD;
      months after progressive disease for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Anticipated">March 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) (Arms A and B)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as an objective status of complete response (CR) or partial response (PR) evaluated by Response Evaluation Criteria in Lymphoma (RECIL) criteria after 2 courses of treatment in all arms. Will be compared between the two arms. The proportion of successes will be estimated in each arm by the number of successes divided by the total number of evaluable patients. Exact binomial ninety-five percent confidence intervals for the true success proportion will be calculated in each arm. For the diffuse large B-cell lymphoma (DLBCL) arms, comparison of overall response rates between the two treatment groups will be performed using a one-sided chi-square test at significance level 0.10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR (Arm C)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as an objective status of CR or PR evaluated by RECIL criteria after 2 cycles of treatment. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial ninety-five percent confidence intervals for the true success proportion will be calculated in each arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematologic response (HI) rate (Arm D)</measure>
    <time_frame>At 20 weeks</time_frame>
    <description>Defined as an objective status of HI-E (minor or major response), HI-P, or HI-N evaluated by Myelodysplastic Syndrome International Working Group 2018 criteria at 20 weeks. Exact binomial ninety-five percent confidence intervals for the true success proportion will be calculated in each arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (Arms A, B, and C)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be estimated in each arm by the number of patients who achieve a CR, PR, minor response (MR), or stable disease (SD) on the cycle 2 response assessment divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success rate will be calculated. The clinical benefit rate will be compared between the DLBCL arms using the chi-square test (or Fisher's exact test if the data in the contingency table is sparse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From registration to death due to any cause, assessed up to 2 years</time_frame>
    <description>The distribution of overall survival will be estimated in each arm using the method of Kaplan-Meier. In the DLBCL arms, the comparison of overall survival between the two treatment arms will be based on the log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of first treatment to the earliest date of documentation of disease progression or death due to any cause, assessed up to 2 years</time_frame>
    <description>The distribution of progression-free survival will be estimated in each arm using the method of Kaplan-Meier. In the DLBCL arms, the comparison of progression-free survival between the two treatment arms will be based on the log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of transplant eligible patients proceeding to transplant (Arms A, B and C)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be estimated in each arm by the number of patients proceeding to transplant divided by the total number of patients who were considered transplant eligible. Exact binomial 95% confidence intervals for the true success rate will be calculated. The rate will be compared between the DLBCL arms using the chi-square test (or Fisher's exact test if the data in the contingency table is sparse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion dependency (Arm D)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Transfusion dependency will be summarized descriptively. The number of patients transfusion dependent at baseline and during follow-up will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assessed using Common Terminology Criteria for Adverse Events (CTCAE). The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. In the DLBCL arms, the overall adverse event rates for Grade 3 or higher hematologic and non-hematologic adverse events at least possibly related to treatment will be compared between the two treatment groups using the chi-square test (or Fisher's exact test if the data in the contingency table is sparse). The rate of febrile neutropenia will be evaluated in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assessed using Patient Reported Outcomes (PRO)-CTCAE (Arms A and B). PRO-CTCAE scores range from 0-4, with corresponding response choices for frequency (Never / Rarely / Occasionally / Frequently / Almost constantly), for severity (None / Mild / Moderate / Severe / Very severe) and interference (Not at all / A little bit / Somewhat / Quite a bit / Very much). The scores for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. PRO-CTCAE scores will be compared between the two treatment groups using the chi-square test (or Fisher's exact test if the data in the contingency table is sparse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continued salvage therapy beyond cycle 2 (Arm A, B and C)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be assessed by evaluating the number of patients who achieve an improved response after cycle 4 compared to the cycle 2 assessment in patients who received additional cycles of ascorbic acid/placebo added to salvage therapy beyond cycle 2. In addition, the number of patients who changed salvage therapies after cycle 2 will be assessed. This analysis will be primarily descriptive.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarker analysis on blood and tissue (Arms A, B, and C)</measure>
    <time_frame>Baseline up to 2 years</time_frame>
    <description>Will consider the correlative research exploratory.</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarker analysis (Arm D)</measure>
    <time_frame>Baseline up to 2 years</time_frame>
    <description>Variant allele frequency (VAF), biomarkers levels from Olink study, values of the cytokines, endothelial dysfunction, inflammation markers and levels of 5mc/5hmc will be measured at baseline, after completion of treatment (at 20 weeks), and at one-year post-registration. Values will be summarized graphically and descriptively at each time point and changes across time will be explored. Due to small sample size, these correlative analyses will be considered exploratory.</description>
  </other_outcome>
  <other_outcome>
    <measure>Molecular response (Arm D)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as a 2 standard deviation reduction in VAF from baseline VAF. Exact binomial 95% confidence intervals for the true success rate will be calculated.</description>
  </other_outcome>
  <other_outcome>
    <measure>TET2 activity (Arm D)</measure>
    <time_frame>At baseline and weeks 12, 20, 52</time_frame>
    <description>Values will be summarized graphically and descriptively at each time point and changes across time will be explored.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Clonal Cytopenia of Undetermined Significance</condition>
  <condition>High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements</condition>
  <condition>Recurrent Diffuse Large B-Cell Lymphoma</condition>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Recurrent Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <condition>Refractory Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A (ascorbic acid, combination chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (placebo, combination chemotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according standard regimen schedule. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (ascobic acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ascorbic acid IV TIW. Treatments repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (ascorbic acid, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm D (ascobic acid)</arm_group_label>
    <other_name>2-(1,2-dihydroxyethyl)-4,5-dihydroxy-furan-3-one</other_name>
    <other_name>Asorbicap</other_name>
    <other_name>C Vitamin</other_name>
    <other_name>C-Long</other_name>
    <other_name>Ce-Vi-Sol</other_name>
    <other_name>Cecon</other_name>
    <other_name>Cenolate</other_name>
    <other_name>Cetane</other_name>
    <other_name>Cevalin</other_name>
    <other_name>L-Ascorbic Acid</other_name>
    <other_name>VIT C</other_name>
    <other_name>Vitamin C</other_name>
    <other_name>Vitamin-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm A (ascorbic acid, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (placebo, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm A (ascorbic acid, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (placebo, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone''s Chloride</other_name>
    <other_name>Peyrone''s Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm A (ascorbic acid, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (placebo, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm A (ascorbic acid, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (placebo, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decadron DP</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Dxevo</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hemady</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>TaperDex</other_name>
    <other_name>Visumetazone</other_name>
    <other_name>ZoDex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm A (ascorbic acid, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (placebo, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>FF 10832</other_name>
    <other_name>FF-10832</other_name>
    <other_name>FF10832</other_name>
    <other_name>Gemcitabine HCI</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm A (ascorbic acid, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (placebo, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <other_name>Asta Z 4942</other_name>
    <other_name>Asta Z-4942</other_name>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>Holoxane</other_name>
    <other_name>Ifex</other_name>
    <other_name>IFO</other_name>
    <other_name>IFO-Cell</other_name>
    <other_name>Ifolem</other_name>
    <other_name>Ifomida</other_name>
    <other_name>Ifomide</other_name>
    <other_name>Ifosfamidum</other_name>
    <other_name>Ifoxan</other_name>
    <other_name>IFX</other_name>
    <other_name>Iphosphamid</other_name>
    <other_name>Iphosphamide</other_name>
    <other_name>Iso-Endoxan</other_name>
    <other_name>Isoendoxan</other_name>
    <other_name>Isophosphamide</other_name>
    <other_name>Mitoxana</other_name>
    <other_name>MJF 9325</other_name>
    <other_name>MJF-9325</other_name>
    <other_name>Naxamide</other_name>
    <other_name>Seromida</other_name>
    <other_name>Tronoxal</other_name>
    <other_name>Z 4942</other_name>
    <other_name>Z-4942</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (ascorbic acid, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (placebo, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm D (ascobic acid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Ai Heng</other_name>
    <other_name>Aiheng</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Diaminocyclohexane Oxalatoplatinum</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Eloxatine</other_name>
    <other_name>JM-83</other_name>
    <other_name>Oxalatoplatin</other_name>
    <other_name>Oxalatoplatinum</other_name>
    <other_name>RP 54780</other_name>
    <other_name>RP-54780</other_name>
    <other_name>SR-96669</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given normal saline IV</description>
    <arm_group_label>Arm B (placebo, combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (ascorbic acid, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (placebo, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (ascorbic acid and combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm D (ascobic acid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (ascorbic acid, combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (placebo, combination chemotherapy)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab ABBS</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar JHL1101</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>Rituximab Biosimilar SIBP-02</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>rituximab-abbs</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven relapsed or refractory lymphomas; relapsed is defined as a relapse that&#xD;
             occurred after having a response to the last therapy that lasted &gt; 6 months;&#xD;
             refractory is no response or relapse within 6 months; previous biopsies &lt; 6 months&#xD;
             prior to treatment on this protocol will be acceptable&#xD;
&#xD;
               -  NOTE: Arms A/B - relapsed or refractory DLBCL within 24 months from the end of&#xD;
                  anthracycline-based therapy; no prior salvage therapy; patients can have received&#xD;
                  radiation therapy as part of initial treatment but not specifically for relapse&#xD;
&#xD;
               -  NOTE: Arm C patients include relapsed lymphoma patients of any type for which the&#xD;
                  recommended treatment includes one of the platinum-based regimens; of note,&#xD;
                  relapsed double-hit high grade lymphoma patients and relapsed Hodgkin lymphoma&#xD;
                  patients will be enrolled in Arm C; there is no limit on the number of prior&#xD;
                  therapies for Arm C patients; the patient must be eligible for a platinum-based&#xD;
                  regimen and must not have received the same regimen in the past without&#xD;
                  responding&#xD;
&#xD;
          -  Measurable or assessable disease: measurable disease is defined as measurable by&#xD;
             computed tomography (CT) (dedicated CT or the CT portion of a positron emission&#xD;
             tomography [PET]/CT) or magnetic resonance imaging (MRI): to be considered measurable,&#xD;
             there must be at least one lesion that has a single diameter of &gt;= 1.5 cm&#xD;
&#xD;
               -  NOTE: Skin lesions can be used if the area is &gt;= 1.5 cm in at least one diameter&#xD;
                  and photographed with a ruler; patients with assessable disease by PET are also&#xD;
                  eligible as long as the assessable disease is biopsy proven lymphoma&#xD;
&#xD;
          -  Arms A/B - eligible for treatment with ifosfamide, carboplatin, and etoposide (+/-&#xD;
             rituximab)&#xD;
&#xD;
          -  Arm C eligible for treatment with one of the following standard, every 3 week,&#xD;
             platinum-based salvage regimens (with or without monoclonal antibody as appropriate&#xD;
             for the disease):&#xD;
&#xD;
               -  Ifosfamide/carboplatin/etoposide (ICE) or&#xD;
                  rituximab/ifosfamide/carboplatin/etoposide (RICE);&#xD;
&#xD;
               -  Cisplatin, cytarabine (cytosine arabinoside), dexamethasone (DHAP) or RDHAP;&#xD;
&#xD;
               -  Gemcitabine hydrochloride (gemcitabine), dexamethasone, cisplatin (GDP) or&#xD;
                  rituximab, gemcitabine, dexamethasone, cisplatin (RGDP);&#xD;
&#xD;
               -  Gemcitabine and oxaliplatin (GemOx) or rituximab, gemcitabine and oxaliplatin&#xD;
                  (RGemOx);&#xD;
&#xD;
               -  Oxaliplatin, cytosine arabinoside, dexamethasone (OAD) or rituximab, oxaliplatin,&#xD;
                  cytosine arabinoside, dexamethasone (ROAD)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2&#xD;
&#xD;
          -  Hemoglobin &gt;= 8.0 g/dL (may transfuse to meet this requirement), obtained =&lt; 14 days&#xD;
             prior to registration&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3, obtained =&lt; 14 days prior to&#xD;
             registration&#xD;
&#xD;
          -  Platelet count &gt;= 75000/mm^3, obtained =&lt; 14 days prior to registration&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 x upper limit of normal (ULN) (if &gt; 2 x ULN direct bilirubin is&#xD;
             required and should be =&lt; 1.5 x ULN), obtained =&lt; 14 days prior to registration&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate transaminase (AST) =&lt; 3 x ULN (=&lt; 5 x ULN&#xD;
             for patients with liver involvement), obtained =&lt; 14 days prior to registration&#xD;
&#xD;
          -  Creatinine =&lt; 1.6 mg/dL; if over 1.6 then the calculated creatinine clearance must be&#xD;
             &gt;= 55 ml/min using the Cockcroft-Gault formula, obtained =&lt; 7 days prior to&#xD;
             registration&#xD;
&#xD;
          -  Negative pregnancy test done =&lt; 7 days prior to registration, for persons of&#xD;
             childbearing potential only&#xD;
&#xD;
               -  NOTE: If the urine test is positive or cannot be confirmed as negative, a serum&#xD;
                  pregnancy test will be required&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) test done =&lt; 14 days prior to registration&#xD;
&#xD;
               -  If positive, the CD4 count must be &gt; 400&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
          -  Willingness to have a central venous line (peripherally inserted central catheter&#xD;
             [PICC] or PORT)&#xD;
&#xD;
          -  Willingness to provide mandatory blood specimens for correlative research&#xD;
&#xD;
          -  Willingness to provide mandatory tissue specimens for correlative research&#xD;
&#xD;
          -  Willingness to return to enrolling institution for follow-up (during the active&#xD;
             monitoring phase of the study)&#xD;
&#xD;
          -  Willingness to follow the requirements of the intravenous ascorbic acid program&#xD;
             schedule&#xD;
&#xD;
          -  ARM D: Patients who had a diagnosis of CCUS with one or more TET2 mutations or TET2&#xD;
             mutations with concurrent splicing genes mutations (SRSF2, U2AF1, SF3B1, and ZRSR2) or&#xD;
             epigenetic regulator mutations (DNMT3A, EZH2, IDH1, IDH2). CCUS diagnosis being&#xD;
             defined based on the absence of definitive morphologic evidence of hematologic&#xD;
             neoplasms from bone marrow biopsy evaluation combined with evidence of pathogenic&#xD;
             myeloid somatic mutation with a variant allele frequency (VAF) of at least 2% using&#xD;
             our institution's next generation sequencing (NGS) panel (OncoHeme, Mayo Clinic)&#xD;
&#xD;
          -  ARM D: ECOG performance status (PS) 0, 1 or 2&#xD;
&#xD;
          -  ARM D: Patients must meet at least 1 of these 3 laboratory criteria to be enrolled:&#xD;
&#xD;
               -  Hemoglobin =&lt; 10g/dL (obtained =&lt; 7 days prior to registration)&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) =&lt; 1000/mm^3 (obtained =&lt; 7 days prior to&#xD;
                  registration)&#xD;
&#xD;
               -  Platelet count =&lt; 100,000/mm^ 3 (obtained =&lt; 7 days prior to registration)&#xD;
&#xD;
          -  ARM D: Total bilirubin =&lt; 2 x ULN (if &gt; 2 x ULN direct bilirubin is required and&#xD;
             should be =&lt; 1.5 x ULN) (obtained =&lt;7 days prior to registration)&#xD;
&#xD;
          -  ARM D: Alanine aminotransferase (ALT) and aspartate transaminase (AST) =&lt; 3 x ULN (=&lt;&#xD;
             5 x ULN for patients with liver involvement) (obtained =&lt;7 days prior to registration)&#xD;
&#xD;
          -  ARM D: Creatinine =&lt; 1.6 mg/dL (obtained =&lt;7 days prior to registration). If &gt; 1.6,&#xD;
             then the Calculated creatinine clearance must be &gt;= 55 ml/min using the&#xD;
             Cockcroft-Gault formula&#xD;
&#xD;
          -  ARM D: Negative pregnancy test, for persons of childbearing potential only (obtained&#xD;
             =&lt; 7 days prior to registration). NOTE: If the urine test is positive or cannot be&#xD;
             confirmed as negative, a serum pregnancy test will be required.&#xD;
&#xD;
          -  ARM D: Provide written informed consent&#xD;
&#xD;
          -  ARM D: Willingness to have a central venous line (PICC or PORT)&#xD;
&#xD;
          -  ARM D: Willingness to provide mandatory blood specimens for correlative research&#xD;
&#xD;
          -  ARM D: Willingness to return to enrolling institution (MCR) for follow-up (during the&#xD;
             active monitoring phase of the study)&#xD;
&#xD;
          -  ARM D: Willingness to follow the requirements of the intravenous ascorbic acid program&#xD;
             schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               -  Pregnant persons&#xD;
&#xD;
               -  Nursing persons&#xD;
&#xD;
               -  Persons of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception&#xD;
&#xD;
          -  Any therapy =&lt; 2 weeks prior to registration; NOTE: Exception: patients on ibrutinib&#xD;
             or corticosteroids (any dose) may continue therapy up until the new regimen has&#xD;
             started at investigator discretion; corticosteroids can be tapered to lowest possible&#xD;
             dose after start of treatment at investigator discretion. Exception: Palliative&#xD;
             radiation is allowed&#xD;
&#xD;
          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment&#xD;
             of the investigator, would make the patient inappropriate for entry into this study or&#xD;
             interfere significantly with the proper assessment of safety and toxicity of the&#xD;
             prescribed regimens&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, pulmonary congestion or pulmonary&#xD;
             edema, clinical dehydration, unstable angina pectoris, cardiac arrhythmia, or&#xD;
             psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Receiving any other investigational agent which would be considered as a treatment for&#xD;
             the lymphoma&#xD;
&#xD;
          -  Other active malignancy than lymphoma&#xD;
&#xD;
               -  NOTE: If there is a history of prior malignancy, they must not be receiving other&#xD;
                  specific treatment for their cancer that could interfere with this protocol&#xD;
                  therapy; patients on hormonal therapy for treated breast or prostate cancer are&#xD;
                  permitted if they meet other eligibility criteria; patients with non-melanotic&#xD;
                  skin cancer may enroll&#xD;
&#xD;
          -  History of myocardial infarction =&lt; 6 months, or current symptomatic congestive heart&#xD;
             failure or left ventricular ejection fraction (LVEF) &lt; 40% or with &gt; grade 2 diastolic&#xD;
             dysfunction, with no symptoms or signs of heart failure&#xD;
&#xD;
          -  Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of&#xD;
             normal)&#xD;
&#xD;
          -  Patients with active central nervous system (CNS) lymphoma or active cerebrospinal&#xD;
             fluid (CSF) involvement with malignant cells requiring CNS-specific therapy with IV or&#xD;
             intrathecal (IT) methotrexate (MTX); Note: Patients with any prior CNS lymphoma&#xD;
             (parenchymalor leptomeningeal) MUST be in complete remission (CR) in those&#xD;
             compartments without any maintenance therapy required&#xD;
&#xD;
          -  Patients with uncontrolled or symptomatic kidney stones; NOTE: Patients with calcium&#xD;
             oxalate crystals on baseline urinalysis or a history of symptomatic calcium oxalate&#xD;
             stones must be seen or have an e-consult by the Nephrology Stone Clinic and placed on&#xD;
             a low oxalate diet (&lt; 100 mg oxalate/day) prior to enrollment&#xD;
&#xD;
          -  Known paroxysmal nocturnal hemoglobinuria (PNH)&#xD;
&#xD;
          -  ARM D: Bona-fide hematological neoplasm&#xD;
&#xD;
          -  ARM D: Any of the following because this study involves an agent that has known&#xD;
             genotoxic, mutagenic and teratogenic effects:&#xD;
&#xD;
               -  Pregnant persons&#xD;
&#xD;
               -  Nursing persons&#xD;
&#xD;
               -  Persons of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception&#xD;
&#xD;
          -  ARM D: Co-morbid systemic illnesses or other severe concurrent disease which, in the&#xD;
             judgment of the investigator, would make the patient inappropriate for entry into this&#xD;
             study or interfere significantly with the proper assessment of safety and toxicity of&#xD;
             the prescribed regimens&#xD;
&#xD;
          -  ARM D: Uncontrolled intercurrent illness including, but not limited to, ongoing or&#xD;
             active infection, symptomatic congestive heart failure, pulmonary congestion or&#xD;
             pulmonary edema, clinical dehydration, unstable angina pectoris, cardiac arrhythmia,&#xD;
             or psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  ARM D: History of myocardial infarction =&lt; 6 months, or current symptomatic congestive&#xD;
             heart failure or known LVEF &lt; 40% or with &gt; grade 2 diastolic dysfunction, with no&#xD;
             symptoms or signs of heart failure&#xD;
&#xD;
          -  ARM D: Patients with uncontrolled or symptomatic kidney stones. NOTE: Patients with&#xD;
             calcium oxalate crystals on baseline urinalysis or a history of symptomatic calcium&#xD;
             oxalate stones must be seen or have an e-consult by the Nephrology Stone Clinic and&#xD;
             placed on a low oxalate diet (&lt;100 mg oxalate/day) prior to enrollment&#xD;
&#xD;
          -  ARM D: Known paroxysmal nocturnal hemoglobinuria (PNH)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas E Witzig</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Craig B. Reeder, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Taimur Sher, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Umar Farooq</last_name>
      <email>umar-farooq@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Umar Farooq</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas E. Witzig, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System-Franciscan Healthcare</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Heaney</last_name>
      <phone>608-392-6810</phone>
      <email>Heaney.Traci@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Traci Heaney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

